Business Description
Eli Lilly and Co
NAICS : 325412
SIC : 2834
ISIN : US5324571083
Share Class Description:
XSWX:LLY: Ordinary SharesCompare
Compare
Traded in other countries / regions
LLY.USALLY.CanadaLILY34.BrazilLLY.ArgentinaLLY.GermanyLLY.Mexico1LLY.ItalyLLYC.AustriaLLYCL.ChileLLY.BulgariaLLY.SwitzerlandLLY.FranceLEL.UK IPO Date
1995-12-08Description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.12 | |||||
| Equity-to-Asset | 0.19 | |||||
| Debt-to-Equity | 2.13 | |||||
| Debt-to-EBITDA | 2.57 | |||||
| Interest Coverage | 22.56 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 9.57 | |||||
| Beneish M-Score | -1.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12 | |||||
| 3-Year EBITDA Growth Rate | -1 | |||||
| 3-Year EPS without NRI Growth Rate | -7.3 | |||||
| 3-Year Book Growth Rate | 26.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 69.12 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 27.3 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 2.34 | |||||
| 9-Day RSI | 16.72 | |||||
| 14-Day RSI | 29.67 | |||||
| 6-1 Month Momentum % | 8.7 | |||||
| 12-1 Month Momentum % | 38.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.11 | |||||
| Quick Ratio | 0.87 | |||||
| Cash Ratio | 0.12 | |||||
| Days Inventory | 273.38 | |||||
| Days Sales Outstanding | 81.94 | |||||
| Days Payable | 125.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.59 | |||||
| Dividend Payout Ratio | 0.54 | |||||
| 3-Year Dividend Growth Rate | 15.2 | |||||
| Forward Dividend Yield % | 0.6 | |||||
| 5-Year Yield-on-Cost % | 1.19 | |||||
| 3-Year Average Share Buyback Ratio | 2 | |||||
| Shareholder Yield % | -0.34 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 80.75 | |||||
| Operating Margin % | 36.28 | |||||
| Net Margin % | 18.86 | |||||
| FCF Margin % | -9.26 | |||||
| ROE % | 61.77 | |||||
| ROA % | 11.75 | |||||
| ROIC % | 25.06 | |||||
| 3-Year ROIIC % | 15.99 | |||||
| ROC (Joel Greenblatt) % | 67.68 | |||||
| ROCE % | 24.2 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 104.29 | |||||
| Forward PE Ratio | 38.06 | |||||
| PE Ratio without NRI | 93.16 | |||||
| Shiller PE Ratio | 151.65 | |||||
| PEG Ratio | 8.71 | |||||
| PS Ratio | 19.65 | |||||
| PB Ratio | 56.22 | |||||
| Price-to-Tangible-Book | 657.89 | |||||
| Price-to-Operating-Cash-Flow | 169.37 | |||||
| EV-to-EBIT | 86.48 | |||||
| EV-to-Forward-EBIT | 34.39 | |||||
| EV-to-EBITDA | 74.05 | |||||
| EV-to-Forward-EBITDA | 32.26 | |||||
| EV-to-Revenue | 21.36 | |||||
| EV-to-Forward-Revenue | 14.35 | |||||
| EV-to-FCF | -229.19 | |||||
| Price-to-Projected-FCF | 14.77 | |||||
| Price-to-Median-PS-Value | 3.41 | |||||
| Price-to-Peter-Lynch-Fair-Value | 11.96 | |||||
| Price-to-Graham-Number | 52.19 | |||||
| Earnings Yield (Greenblatt) % | 1.16 | |||||
| FCF Yield % | -0.45 | |||||
| Forward Rate of Return (Yacktman) % | 8.16 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eli Lilly and Co Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 34,527.449 | ||
| EPS (TTM) (CHF) | 7.175 | ||
| Beta | -0.1 | ||
| Volatility % | 28.24 | ||
| 14-Day RSI | 29.67 | ||
| 14-Day ATR (CHF) | 0.552922 | ||
| 20-Day SMA (CHF) | 750 | ||
| 12-1 Month Momentum % | 38.89 | ||
| 52-Week Range (CHF) | 500 - 830 | ||
| Shares Outstanding (Mil) | 900.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eli Lilly and Co Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eli Lilly and Co Stock Events
| Event | Date | Price(CHF) | ||
|---|---|---|---|---|
| No Event Data | ||||
Eli Lilly and Co Frequently Asked Questions
What is Eli Lilly and Co(XSWX:LLY)'s stock price today?
The current price of XSWX:LLY is CHF750.00. The 52 week high of XSWX:LLY is CHF830.00 and 52 week low is CHF500.00.
When is next earnings date of Eli Lilly and Co(XSWX:LLY)?
The next earnings date of Eli Lilly and Co(XSWX:LLY) is 2025-01-30 Est..
Does Eli Lilly and Co(XSWX:LLY) pay dividends? If so, how much?
The Dividend Yield %  of Eli Lilly and Co(XSWX:LLY) is 0.59% (As of Today), Highest Dividend Payout Ratio of Eli Lilly and Co(XSWX:LLY) was 0.72. The lowest was 0.37. And the median was 0.49. The  Forward Dividend Yield % of Eli Lilly and Co(XSWX:LLY) is 0.6%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers